Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. (Otsuka) has announced an agreement with Eisai Inc. (Eisai), a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen® and to an enzyme inhibitor, E7727.

Purpose and Significance of the Agreement

Otsuka's activities in the area of hematological malignancies began in March 2008 with the promotion of IV Busulfex®, a conditioning agent used prior to hematopoietic stem cell transplantation in patients with chronic myeloid leukemia. Since 2010, Otsuka has co-promoted Sprycel® in a joint venture with Bristol-Myers Squibb for treatment of patients in Japan, the U.S. and Europe with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Otsuka also has in phase II clinical trials a prodrug subcutaneous injection of decitabine, SGI-110. With Dacogen®, and potentially in the future with SGI-110 and ASTX727, Otsuka aims to further improve the quality of treatments available to patients with hematological malignancies.

Source:

Otsuka Pharmaceutical Co., Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies six cancer susceptibility genes